Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.

Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM

The Journal of clinical endocrinology and metabolism23 Mar 2011Cited by 79 (Europe PMC)

PMID21430030DOI10.1210/jc.2010-2520PepBankPUB-21430030

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome
In a postmenopausal woman receiving teriparatide with calcium and vitamin D, MRI showed decreased fracture-site edema after 6 months.
In plain wordsIn one woman, fracture-site swelling decreased during teriparatide, calcium and vitamin D treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFracture-site edema
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Teriparatide treatment commenced, and 6 months later, a repeat MRI showed decreased edema at the fracture sites with faint cortical bridging.
1 context sentence(design, population, supporting numbers)
Title · context
Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2143003001
02HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome
In a postmenopausal woman receiving teriparatide with calcium and vitamin D, MRI showed faint cortical bridging after 6 months.
In plain wordsIn one woman, MRI showed early bone bridging during teriparatide, calcium and vitamin D treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bridging
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Teriparatide treatment commenced, and 6 months later, a repeat MRI showed decreased edema at the fracture sites with faint cortical bridging.
1 context sentence(design, population, supporting numbers)
Title · context
Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2143003002
03HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome
In a postmenopausal woman receiving teriparatide with calcium and vitamin D, thigh pain disappeared over the next year.
In plain wordsIn one woman, thigh pain disappeared during teriparatide, calcium and vitamin D treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseThigh pain
Study
n = 1
Outcome group
Pain · Musculoskeletal
Source sentences
Summary
Thigh pain and lower limb weakness disappeared over the next year, and complete fracture healing was established (MRI).
1 context sentence(design, population, supporting numbers)
Title · context
Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2143003003
04HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome
In a postmenopausal woman receiving teriparatide with calcium and vitamin D, lower limb weakness disappeared over the next year.
In plain wordsIn one woman, leg weakness disappeared during teriparatide, calcium and vitamin D treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLower limb weakness
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Thigh pain and lower limb weakness disappeared over the next year, and complete fracture healing was established (MRI).
1 context sentence(design, population, supporting numbers)
Title · context
Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2143003004
05HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesEfficacy outcome
In a postmenopausal woman receiving teriparatide with calcium and vitamin D, MRI established complete fracture healing.
In plain wordsIn one woman, MRI confirmed complete fracture healing during teriparatide, calcium and vitamin D treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFracture healing
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Thigh pain and lower limb weakness disappeared over the next year, and complete fracture healing was established (MRI).
1 context sentence(design, population, supporting numbers)
Title · context
Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2143003005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.